Yokohama Capital
VC Fund
Yokohama, Japan
Yokohama Capital is a VC fund in Yokohama focused on Artificial Intelligence and Software. Yokohama Capital as a venture capital firm conducts investment and rehabilitation support for small and medium-sized companies.
- Total investments:
- 51
- Last investment:
- Lead investor:
- 8%
Last updated:
For AI agents: llms.txt
Industries Yokohama Capital invests in
Stages Yokohama Capital invests in
Countries Yokohama Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Series A
- $272k–$85M
- Series B
- $2.8M–$67M
Investment Focus
Industry
- Artificial Intelligence 8 (16%)
- Software 7 (14%)
- Health Care 6 (12%)
- Biotechnology 6 (12%)
- Information Technology 6 (12%)
Stage
- Funding Round 15 (29%)
- Series A 10 (20%)
- Series B 6 (12%)
- Series D 6 (12%)
- Seed 5 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Hidetaka Fujita
Deputy General Manager
|
Deputy General Manager | Total investments: 2 | Find email | |
Shunji Tanabe
President and Representative Director
|
President and Representative Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Varinos
|
Varinos is a clinical laboratory contract analysis company that is a partner of medical institutions. Varinos provides genomic testing development and contract analysis services using the latest technology, the next-generation sequencer. | $7.9M / Series D / May 12, 2026 | |
JPYC
|
JPYC is a financial institution that issues the community stablecoin JPYC, which is pegged to the yen of Japanese. They want to create a society where everyone can develop by fusing the real world with the world of cryptocurrencies and increasing the liquidity of capital to achieve their goal of overcoming the social conundrum. It will promotecapital's liquidity and create an environment that helps in development for all. | $17.6M / Series B / Apr 20, 2026 | |
Reborna Biosciences
|
Reborna Biosciences provides research and development in the field of genetic diseases. The company develops therapeutic options for area of unmet medical needs in genetic rare disease. The company's technology enables low-molecular compounds to target ribonucleic acid. The company provides new disease-modifying drugs for patients sufferingfrom rare genetic diseases including spinal muscular atrophy. | $5.3M / Jun 25, 2025 | |
NABLA Mobility
|
NABLA Mobility develops, so-called, "Smart navigation system for Aviation", an adaptive advisory tool to implement better flight trajectories and flight settings. In fact, airspace is usually filled with many uncertainties in the various aspects of flight conditions. Our solution utilizes the power of AI/ML in the algorithms of dataplatform and optimization solvers and we contribute to augment the operational excellence and the decarbonization of the aviation industry. | $2.8M / Series A / May 01, 2025 | |
GooPass
|
GooPass is a subscription-based camera equipment rental platform that offers users cameras, interchangeable lenses, and drones. It also allows users to buy or rent photography equipment by reserving it online. | Series C / Jan 31, 2025 | |
PXP
|
PXP is a green tech development firm that develops clean energy using next-generation photoelectric conversion elements. | $10M / Series A / Dec 04, 2024 | |
Any
|
any. develops and offers knowledge sharing tool Qast. | $7M / Series B / Dec 04, 2024 | |
LexxPluss
|
LexxPluss develops an automatic transfer software system and robot hardware. | $4.5M / Series A / Sep 12, 2024 | |
KOMPEITO
|
Office de Yasai is an online platform that enables users to order and get vegetables delivered to their offices. The platform’s operations are based in Tokyo, Japan. | $7.4M / Series D / Aug 20, 2024 | |
ZABoooN
|
ZABoooN is a shipping company that offers crew labor management, movement management, and ship management services. | $2.7M / Series A / Aug 07, 2024 | |
| See all 51 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Yokohama Capital invest in?
Yokohama Capital invests primarily in Artificial Intelligence, Software and Health Care startups, most often at Funding Round and Series A stage. Most of the 51 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Yokohama Capital's check size?
Yokohama Capital typically joins rounds of $272k–$85M at Series A and $2.8M–$67M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Yokohama Capital participates in.
How do I contact Yokohama Capital?
Public channels for Yokohama Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Yokohama Capital?
The team at Yokohama Capital includes Hidetaka Fujita (Deputy General Manager) and Shunji Tanabe (President and Representative Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
